

## [Hematology analyzer cleared, 11/16](#)

written by CAP TODAY  
November 16, 2016

November 2016—Mindray has received 510(k) clearance from the Food and Drug Administration to market and sell the Mindray BC-5390 Auto Hematology Analyzer. The Mindray BC-5390 analyzer is designed to meet the testing needs of mid-volume hematology laboratories while offering features commonly found on large-volume analyzers.



©2026 CAP TODAY, all rights reserved.

---

## [Low protein binding micro tubes, 11/16](#)

written by CAP TODAY  
November 16, 2016

November 2016—Sarstedt offers low protein binding micro tubes in 0.5 mL, 1.5 mL, and 2.0 mL volumes. These tubes are designed to meet the requirements of protein analytics while maximizing protein recovery rates. The micro tubes are manufactured from a proprietary polypropylene with low protein binding properties and do not feature any potentially contaminating surface coating like silicone.



©2026 CAP TODAY, all rights reserved.

---

## [Cardiac, metabolic markers catalog, 11/16](#)

written by CAP TODAY

November 16, 2016

November 2016—Meridian Life Science released a new catalog that provides a detailed overview of the company's cardiac and metabolic markers for assay development. Meridian's top-performing cardiac and metabolic markers include Lp-PLA2, CRP, D-dimer, troponin, NT-proBNP, myoglobin, procalcitonin, FABP, PAPP-A, fibrinogen, sCD40L, MPO, NSE, and galectin-3.



©2026 CAP TODAY, all rights reserved.

---

## [In vitro diagnostic DNA blood kit, 11/16](#)

written by CAP TODAY

November 16, 2016

November 2016—U.K.-based Arcis Biotechnology launched its Arcis DNA Blood Kit (IVD) for preparation of DNA from blood using a novel three-minute, two-step system.



©2026 CAP TODAY, all rights reserved.

---

## [Conferences/Events & Webinars](#)

# for Pathologists and Laboratory Professionals

written by CAP TODAY  
November 16, 2016

Tired of scrolling through continuing education offerings that are not applicable to your needs? Your search is about to become a whole lot easier. Visit CAP's NEW Conferences/Events & Webinars Section to easily find continuing education offerings that meet your needs. Search by date, location, event type, and specialty.



©2026 CAP TODAY, all rights reserved.

---

## AMP case report: October 2016 test yourself answers

written by CAP TODAY  
November 16, 2016

November 2016—In the October 2016 issue was a report, “Laser capture microdissection: Vanishing roles in tissue microdissection revalued in salvaging a melanoma with micrometastasis for BRAF V600E mutation detection,” written by members of the Association for Molecular Pathology. Here are answers (in bold) to the three “test yourself” questions that followed that case report.



©2026 CAP TODAY, all rights reserved.

---

# [2017 Advertising Rates](#)

written by CAP TODAY  
November 16, 2016

2018 advertising rates available [here](#).



©2026 CAP TODAY, all rights reserved.

---

# [Labs enter a MALDI-TOF state of mind](#)

written by CAP TODAY  
November 16, 2016

October 2016—When MALDI-TOF mass spectrometry enters the microbiology lab, it's a little like watching Sir John Falstaff settle his considerable girth onstage. Things happen. Characters fret and flee, scheme, opine, panic, and, in the case of Prince Hal, ascend to greatness. (And, if we're honest, some just get drunk.) Both, in brief, are an upending presence.



## **Blood bank: On guard against daratumumab interference**

written by CAP TODAY  
November 16, 2016

October 2016—As fans of spycraft know, offensive counterintelligence can include an arsenal of strategies: initiating a diversion, sowing confusion, creating false identities—anything that makes another party believe something that isn't true. If the cancer treatment drug daratumumab were capable of deceptive intent, it might be accused of all those ploys when it comes to interfering with blood transfusion crossmatching. The reason: For patients receiving daratumumab, marketed as Darzalex by Janssen Pharmaceuticals, antibody testing for transfusion is subject to erratic false-positives, often leaving transfusion services confused, uncertain, and on hold.



## **Study finds what could be a key to prostate cancer progression**

written by CAP TODAY  
November 16, 2016

October 2016—The Gleason classification for prostate cancer is by no means going away. But within the Gleason grade, the presence or absence of a DNA-repair gene mutation may signal who is likely to proceed to invasive cancer, says Colin C. Pritchard, MD, PhD, lead author of a study published Aug. 4 in the New England Journal of Medicine.



©2026 CAP TODAY, all rights reserved.